H. Duffau and L. Capelle, Preferential brain locations of low-grade gliomas, Cancer, vol.991, issue.12, pp.2622-2626, 2004.
DOI : 10.1212/WNL.46.2.508

J. Pallud, E. Mandonnet, and H. Duffau, Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas, Annals of Neurology, vol.22, issue.3, pp.380-383, 2006.
DOI : 10.1016/S0360-3016(01)02720-1

URL : https://hal.archives-ouvertes.fr/inserm-00163977

M. Berger, A. Deliganis, J. Dobbins, and G. Keles, The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas, Cancer, vol.35, issue.6, pp.1784-1791, 1994.
DOI : 10.1016/0360-3016(77)90045-1

J. Smith, E. Chang, and K. Lamborn, Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas, Journal of Clinical Oncology, vol.26, issue.8, pp.1338-1345, 2008.
DOI : 10.1200/JCO.2007.13.9337

R. Soffietti, B. Baumert, and L. Bello, Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force, European Journal of Neurology, vol.27, issue.9, pp.1124-1133, 2010.
DOI : 10.1200/JCO.2008.20.5765

H. Duffau, L. Taillandier, and L. Capelle, Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma, Journal of Neuro-Oncology, vol.6, issue.2, pp.171-176, 2006.
DOI : 10.1007/s11060-006-9168-3

G. Spena, D. Garbossa, L. Barletta, C. Prevost, and P. Versari, Preoperative Chemotherapy for Infiltrative Low-Grade Oligoastrocytoma: a Useful Strategy to Maximize Surgical Resection, Neurologia medico-chirurgica, vol.50, issue.5, pp.410-413, 2010.
DOI : 10.2176/nmc.50.410

M. Blonski, L. Taillandier, and G. Herbet, Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life, Journal of Neuro-Oncology, vol.6, issue.2, 2011.
DOI : 10.1037/h0054651

E. Mandonnet, J. Pallud, and O. Clatz, Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm, Neurosurgical Review, vol.20, issue.6, pp.263-269, 2008.
DOI : 10.1016/S0028-3770(05)83486-1

E. Mandonnet, J. Delattre, and M. Tanguy, Continuous growth of mean tumor diameter in a subset of grade II gliomas, Annals of Neurology, vol.54, issue.4, pp.524-528, 2003.
DOI : 10.1212/WNL.54.7.1442

J. Pallud, E. Mandonnet, and C. Deroulers, Pregnancy increases the growth rates of World Health Organization grade II gliomas, Ann Neurol, vol.67, pp.398-404, 2010.

M. Berger, Functional mapping-guided resection of low-grade gliomas, Clin Neurosurg, vol.42, pp.437-452, 1995.

J. Pallud, L. Capelle, and L. Taillandier, Prognostic significance of imaging contrast enhancement for WHO grade II gliomas, Neuro-Oncology, vol.11, issue.2, pp.176-182, 2009.
DOI : 10.1016/j.surneu.2006.04.015

URL : https://hal.archives-ouvertes.fr/inserm-00349509

H. Duffau, Intraoperative cortico???subcortical stimulations in surgery of low-grade gliomas, Expert Review of Neurotherapeutics, vol.12, issue.4, pp.473-485, 2005.
DOI : 10.1097/00001756-200107200-00023

H. Duffau, Contribution of cortical and subcortical electrostimulation in brain glioma surgery: Methodological and functional considerations, Neurophysiologie Clinique/Clinical Neurophysiology, vol.37, issue.6, pp.373-382, 2007.
DOI : 10.1016/j.neucli.2007.09.003

W. Palmisano, K. Divine, and G. Saccomanno, Predicting lung cancer by detecting aberrant promoter methylation in sputum, Cancer Res, vol.60, pp.5954-5958, 2000.

J. Balss, J. Meyer, and W. Mueller, Analysis of the IDH1 codon 132 mutation in brain tumors, Acta Neuropathologica, vol.6, issue.6, pp.597-602, 2008.
DOI : 10.1093/jnen/59.6.544

Y. Sonoda, T. Kumabe, and T. Nakamura, mutations in Japanese glioma patients, Cancer Science, vol.324, issue.10, pp.1996-1998, 2009.
DOI : 10.1016/B978-0-12-152827-0.50009-8

D. Ricard, G. Kaloshi, and A. Amiel-benouaich, Dynamic history of low-grade gliomas before and after temozolomide treatment, Annals of Neurology, vol.15, issue.5, pp.484-490, 2007.
DOI : 10.1128/MCB.15.8.4249

M. Peyre, S. Cartalat-carel, and D. Meyronet, Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol, 2010.

E. Mandonnet, J. Pallud, and D. Fontaine, Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection, Neurosurgical Review, vol.26, issue.8, pp.91-96, 2010.
DOI : 10.1007/s10143-009-0229-x

URL : https://hal.archives-ouvertes.fr/hal-00492516

E. Mandonnet, L. Capelle, and H. Duffau, Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns, Journal of Neuro-Oncology, vol.12, issue.2, pp.179-185, 2006.
DOI : 10.1016/S0002-9440(10)64183-1

URL : https://hal.archives-ouvertes.fr/inserm-00147499

J. Pallud, B. Devaux, C. Daumas-duport, C. Oppenheim, and F. Roux, Glioma dissemination along the corticospinal tract, Journal of Neuro-Oncology, vol.39, issue.2, pp.239-240, 2005.
DOI : 10.1007/s11060-005-0378-x

H. Duffau, Does post-lesional subcortical plasticity exist in the human brain?, Neuroscience Research, vol.65, issue.2, pp.131-135, 2009.
DOI : 10.1016/j.neures.2009.07.002

F. Pignatti, M. Van-den-bent, and D. Curran, Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma, Journal of Clinical Oncology, vol.20, issue.8, pp.2076-2084, 2002.
DOI : 10.1200/JCO.2002.08.121

M. Kujas, J. Lejeune, and A. Benouaich-amiel, Chromosome 1p loss: A favorable prognostic factor in low-grade gliomas, Annals of Neurology, vol.22, issue.2, pp.322-326, 2005.
DOI : 10.1016/S0360-3016(01)02692-X

R. Jenkins, H. Blair, and K. Ballman, A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma, Cancer Research, vol.66, issue.20, pp.9852-9861, 2006.
DOI : 10.1158/0008-5472.CAN-06-1796

J. Cairncross, K. Ueki, and M. Zlatescu, Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas, JNCI: Journal of the National Cancer Institute, vol.15, issue.19, pp.1473-1479, 1998.
DOI : 10.1200/JCO.1997.15.12.3423

G. Kaloshi, A. Benouaich-amiel, and F. Diakite, Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome, Neurology, vol.68, issue.21, pp.1831-1836, 2007.
DOI : 10.1212/01.wnl.0000262034.26310.a2

C. Houillier, X. Wang, and G. Kaloshi, IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas, Neurology, vol.75, issue.17, pp.1560-1566, 2011.
DOI : 10.1212/WNL.0b013e3181f96282

M. Sanson, Y. Marie, and S. Paris, Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas, Journal of Clinical Oncology, vol.27, issue.25, pp.4150-4154, 2009.
DOI : 10.1200/JCO.2009.21.9832

S. Everhard, G. Kaloshi, and E. Criniere, MGMT methylation: A marker of response to temozolomide in low-grade gliomas, Annals of Neurology, vol.97, issue.6, pp.740-743, 2006.
DOI : 10.1093/jnen/60.8.808

G. Spena, D. Garbossa, L. Barletta, C. Prevost, and P. Versari, Preoperative Chemotherapy for Infiltrative Low-Grade Oligoastrocytoma: a Useful Strategy to Maximize Surgical Resection, Neurologia medico-chirurgica, vol.50, issue.5, pp.410-413, 2010.
DOI : 10.2176/nmc.50.410

H. Duffau, L. Taillandier, and L. Capelle, Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma, Journal of Neuro-Oncology, vol.6, issue.2, pp.171-176, 2006.
DOI : 10.1007/s11060-006-9168-3

A. Voloschin, D. Louis, G. Cosgrove, and T. Batchelor, Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: Case study, Neuro-Oncology, vol.7, issue.1, pp.97-100, 2005.
DOI : 10.1093/neuonc/5.2.128

N. Pouratian, M. Mut, and J. Jagannathan, Low-grade gliomas in older patients: a retrospective analysis of prognostic factors, Journal of Neuro-Oncology, vol.95, issue.3, pp.341-350, 2008.
DOI : 10.1093/jnen/62.2.111

L. Bauchet, V. Rigau, and H. Mathieu-daude, French brain tumor data bank: Methodology and first results on 10,000 cases, Journal of Neuro-Oncology, vol.61, issue.2, pp.189-199, 2007.
DOI : 10.1093/jnen/61.3.215

V. Rigau, S. Zouaoui, and H. Mathieu-daude, French Brain Tumor DataBase (FBTDB): Five years histological results on 25 756 cases, Brain Pathol, 2010.

H. Duffau, J. Pallud, and E. Mandonnet, Evidence for the genesis of WHO grade II glioma in an asymptomatic young adult using repeated MRIs, Acta Neurochirurgica, vol.240, issue.3, pp.473-477, 2010.
DOI : 10.1016/j.jns.2005.09.008

J. Pallud, D. Fontaine, and H. Duffau, Natural history of incidental world health organization grade II gliomas, Annals of Neurology, vol.62, issue.5, pp.727-733, 2010.
DOI : 10.1016/S0360-3016(01)02720-1

E. Mandonnet, J. Delattre, and M. Tanguy, Continuous growth of mean tumor diameter in a subset of grade II gliomas, Annals of Neurology, vol.54, issue.4, pp.524-528, 2003.
DOI : 10.1212/WNL.54.7.1442

E. Mandonnet, L. Capelle, and H. Duffau, Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns, Journal of Neuro-Oncology, vol.12, issue.2, pp.179-185, 2006.
DOI : 10.1016/S0002-9440(10)64183-1

URL : https://hal.archives-ouvertes.fr/inserm-00147499

J. Pallud, B. Devaux, C. Daumas-duport, C. Oppenheim, and F. Roux, Glioma dissemination along the corticospinal tract, Journal of Neuro-Oncology, vol.39, issue.2, pp.239-240, 2005.
DOI : 10.1007/s11060-005-0378-x

S. Jbabdi, E. Mandonnet, and H. Duffau, Simulation of anisotropic growth of low-grade gliomas using diffusion tensor imaging, Magnetic Resonance in Medicine, vol.6, issue.3, pp.616-624, 2005.
DOI : 10.1016/S0002-9440(10)64183-1

J. Pallud, H. Duffau, and R. Razak, Influence of pregnancy in the behavior of diffuse gliomas: clinical cases of a French glioma study group, Journal of Neurology, vol.65, issue.12, pp.2014-2020, 2009.
DOI : 10.1097/01.AOG.0000188061.14425.e2

J. Pallud, E. Mandonnet, and C. Deroulers, Pregnancy increases the growth rates of World Health Organization grade II gliomas, Ann Neurol, vol.67, pp.398-404, 2010.

H. Duffau and L. Capelle, Preferential brain locations of low-grade gliomas, Cancer, vol.991, issue.12, pp.2622-2626, 2004.
DOI : 10.1212/WNL.46.2.508

E. Chang, M. Potts, and G. Keles, Seizure characteristics and control following resection in 332 patients with low-grade gliomas, Journal of Neurosurgery, vol.26, issue.2, pp.227-235, 2008.
DOI : 10.1212/01.WNL.0000079374.78589.1B

G. Bauman, K. Lote, and D. Larson, Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis, International Journal of Radiation Oncology*Biology*Physics, vol.45, issue.4, pp.923-929, 1999.
DOI : 10.1016/S0360-3016(99)00284-9

F. Pignatti, M. Van-den-bent, and D. Curran, Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma, Journal of Clinical Oncology, vol.20, issue.8, pp.2076-2084, 2002.
DOI : 10.1200/JCO.2002.08.121

J. Pallud, E. Mandonnet, and H. Duffau, Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas, Annals of Neurology, vol.22, issue.3, pp.380-383, 2006.
DOI : 10.1016/S0360-3016(01)02720-1

URL : https://hal.archives-ouvertes.fr/inserm-00163977

J. Smith, E. Chang, and K. Lamborn, Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas, Journal of Clinical Oncology, vol.26, issue.8, pp.1338-1345, 2008.
DOI : 10.1200/JCO.2007.13.9337

E. Chang, A. Clark, and R. Jensen, Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System, Journal of Neurosurgery, vol.16, issue.2, pp.203-210, 2009.
DOI : 10.1016/0360-3016(90)90397-3

D. Schomas, N. Laack, and P. Brown, Low-grade gliomas in older patients, Cancer, vol.68, issue.17, pp.3969-3978, 2009.
DOI : 10.1212/WNL.56.5.618

F. Iwamoto, A. Reiner, and L. Nayak, Prognosis and patterns of care in elderly patients with glioma, Cancer, vol.23, issue.23, pp.5534-5540, 2009.
DOI : 10.1093/jnen/64.6.479

A. Pruitt and J. Henson, Equal care for the elderly with low-grade gliomas?, Neurology, vol.73, issue.24, pp.2056-2057, 2009.
DOI : 10.1212/WNL.0b013e3181c67882

D. Schiff, P. Brown, and C. Giannini, Outcome in adult low-grade glioma: The impact of prognostic factors and treatment, Neurology, vol.69, issue.13, pp.1366-1373, 2007.
DOI : 10.1212/01.wnl.0000277271.47601.a1

D. Schomas, N. Laack, and R. Rao, Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic, Neuro-Oncology, vol.11, issue.4, pp.437-445, 2009.
DOI : 10.1200/JCO.2004.10.169

F. Ducray, E. Hallani, S. Idbaih, and A. , Diagnostic and prognostic markers in gliomas, Current Opinion in Oncology, vol.21, issue.6, pp.537-542, 2009.
DOI : 10.1097/CCO.0b013e32833065a7

S. Chang, S. Nelson, and S. Vandenberg, Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma, Journal of Neuro-Oncology, vol.24, issue.3, pp.401-415, 2009.
DOI : 10.2214/ajr.175.1.1750207

J. Pallud, B. Devaux, F. Nataf, and F. Roux, D??limitation spatiale des oligodendrogliomes de bas grade, Neurochirurgie, vol.51, issue.3-4, pp.254-259, 2005.
DOI : 10.1016/S0028-3770(05)83486-1

J. Pallud, P. Varlet, and B. Devaux, Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities, Neurology, vol.74, issue.21, pp.1724-1731, 2011.
DOI : 10.1212/WNL.0b013e3181e04264

J. Pallud, L. Capelle, and L. Taillandier, Prognostic significance of imaging contrast enhancement for WHO grade II gliomas, Neuro-Oncology, vol.11, issue.2, pp.176-182, 2009.
DOI : 10.1016/j.surneu.2006.04.015

URL : https://hal.archives-ouvertes.fr/inserm-00349509

F. Dhermain, P. Hau, H. Lanfermann, A. Jacobs, and M. Van-den-bent, Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas, The Lancet Neurology, vol.9, issue.9, pp.906-920, 2010.
DOI : 10.1016/S1474-4422(10)70181-2

A. Krainik, H. Duffau, and L. Capelle, Role of the healthy hemisphere in recovery after resection of the supplementary motor area, Neurology, vol.62, issue.8, pp.1323-1332, 2004.
DOI : 10.1212/01.WNL.0000120547.83482.B1

URL : https://hal.archives-ouvertes.fr/hal-00349683

S. Lehericy, H. Duffau, and P. Cornu, Correspondence between functional magnetic resonance imaging somatotopy and individual brain anatomy of the central region: comparison with intraoperative stimulation in patients with brain tumors, Journal of Neurosurgery, vol.195, issue.4, pp.589-598, 2000.
DOI : 10.3171/jns.1996.85.4.0608

D. Benedictis, A. Duffau, and H. , Brain Hodotopy: From Esoteric Concept to Practical Surgical Applications, Neurosurgery, vol.60, issue.4, 2011.
DOI : 10.2217/fnl.10.21

M. Law, S. Yang, and H. Wang, Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging, AJNR Am J Neuroradiol, vol.24, pp.1989-1998, 2003.

M. Law, S. Oh, and J. Babb, Low-Grade Gliomas: Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging???Prediction of Patient Clinical Response, Radiology, vol.238, issue.2, pp.658-667, 2006.
DOI : 10.1148/radiol.2382042180

M. Law, R. Young, and J. Babb, Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging, Radiology, vol.247, issue.2, pp.490-498, 2008.
DOI : 10.1148/radiol.2472070898

G. Caseiras, S. Chheang, and J. Babb, Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting, European Journal of Radiology, vol.73, issue.2, pp.215-220, 2010.
DOI : 10.1016/j.ejrad.2008.11.005

F. Dhermain, Role of perfusion, vascular permeability and anatomic MR imaging in radiation therapy for gliomas], Bull Cancer, vol.97, pp.753-758, 2010.

F. Dhermain, G. Saliou, and F. Parker, Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas, Journal of Neuro-Oncology, vol.178, issue.Suppl 7, pp.81-88, 2010.
DOI : 10.2214/ajr.178.3.1780711

A. Stadlbauer, E. Moser, and S. Gruber, Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas, NeuroImage, vol.23, issue.2, pp.454-461, 2004.
DOI : 10.1016/j.neuroimage.2004.06.022

Q. Zeng, H. Liu, K. Zhang, C. Li, and G. Zhou, Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy, Magnetic Resonance Imaging, vol.29, issue.1, pp.25-31, 2011.
DOI : 10.1016/j.mri.2010.07.017

H. Shimizu, T. Kumabe, R. Shirane, and T. Yoshimoto, Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas, AJNR Am J Neuroradiol, vol.21, pp.659-665, 2000.

R. Guillevin, C. Menuel, and H. Duffau, Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas, Journal of Neuro-Oncology, vol.30, issue.6 suppl 19, pp.181-187, 2008.
DOI : 10.2214/ajr.171.6.9843274

P. Murphy, L. Viviers, and C. Abson, Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy, British Journal of Cancer, vol.17, issue.4, pp.781-786, 2004.
DOI : 10.1200/JCO.1999.17.9.2762

R. Guillevin, C. Menuel, and S. Taillibert, Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy, British Journal of Cancer, vol.87, issue.12, pp.1854-1861, 2011.
DOI : 10.3171/jns.1997.87.4.0516

URL : https://hal.archives-ouvertes.fr/hal-01469461

C. Hlaihel, L. Guilloton, and J. Guyotat, Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas, Journal of Neuro-Oncology, vol.29, issue.1, pp.73-80, 2010.
DOI : 10.1093/jnen/61.3.215

E. Hattingen, P. Raab, and K. Franz, Prognostic value of choline and creatine in WHO grade II gliomas, Neuroradiology, vol.19, issue.9, pp.759-767, 2008.
DOI : 10.1016/S0360-3016(96)00352-5

F. Ducray, G. Dutertre, and D. Ricard, Advances in adults' gliomas biology, imaging and treatment], Bull Cancer, vol.97, pp.17-36, 2010.

E. Mandonnet, J. Pallud, and D. Fontaine, Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection, Neurosurgical Review, vol.26, issue.8, pp.91-96, 2010.
DOI : 10.1007/s10143-009-0229-x

URL : https://hal.archives-ouvertes.fr/hal-00492516

M. Peyre, S. Cartalat-carel, and D. Meyronet, Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol, 2010.

D. Ricard, G. Kaloshi, and A. Amiel-benouaich, Dynamic history of low-grade gliomas before and after temozolomide treatment, Annals of Neurology, vol.15, issue.5, pp.484-490, 2007.
DOI : 10.1128/MCB.15.8.4249

R. Jenkins, H. Blair, and K. Ballman, A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma, Cancer Research, vol.66, issue.20, pp.9852-9861, 2006.
DOI : 10.1158/0008-5472.CAN-06-1796

J. Smith, A. Perry, and T. Borell, Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas, Journal of Clinical Oncology, vol.18, issue.3, pp.636-645, 2000.
DOI : 10.1200/JCO.2000.18.3.636

J. Smith, B. Alderete, and Y. Minn, Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype, Oncogene, vol.18, issue.28, pp.4144-4152, 1999.
DOI : 10.1002/gcc.2870110307

H. Ohgaki and P. Kleihues, Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas, Journal of Neuropathology & Experimental Neurology, vol.10, issue.6, pp.479-489, 2005.
DOI : 10.1093/carcin/16.6.1277

B. Campbell, D. Horsman, and J. Maguire, Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status?, Journal of Neuro-Oncology, vol.42, issue.3, pp.37-45, 2008.
DOI : 10.1016/S0002-9440(10)61702-6

N. Thon, S. Eigenbrod, and E. Grasbon-frodl, Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas, Journal of Neuropathology and Experimental Neurology, vol.107, issue.11, pp.1219-1228, 2009.
DOI : 10.1007/BF01405784

J. Cairncross, K. Ueki, and M. Zlatescu, Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas, JNCI: Journal of the National Cancer Institute, vol.15, issue.19, pp.1473-1479, 1998.
DOI : 10.1200/JCO.1997.15.12.3423

T. Watanabe, M. Nakamura, and J. Kros, Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas, Acta Neuropathologica, vol.103, issue.3, pp.267-275, 2002.
DOI : 10.1007/s004010100464

J. Piepmeier, Current concepts in the evaluation and management of WHO grade II gliomas, Journal of Neuro-Oncology, vol.91, issue.1, pp.253-259, 2009.
DOI : 10.1016/S0360-3016(96)00352-5

F. Ducray, Biology of gliomas]. Cancer Radiother, pp.663-668, 2008.

M. Kujas, J. Lejeune, and A. Benouaich-amiel, Chromosome 1p loss: A favorable prognostic factor in low-grade gliomas, Annals of Neurology, vol.22, issue.2, pp.322-326, 2005.
DOI : 10.1016/S0360-3016(01)02692-X

K. Hoang-xuan, L. Capelle, and M. Kujas, Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions, Journal of Clinical Oncology, vol.22, issue.15, pp.3133-3138, 2004.
DOI : 10.1200/JCO.2004.10.169

A. Idbaih, Y. Marie, and G. Pierron, Two types of chromosome 1p losses with opposite significance in gliomas, Annals of Neurology, vol.11, issue.3, pp.483-487, 2005.
DOI : 10.1093/jnen/64.1.10

URL : https://hal.archives-ouvertes.fr/inserm-00310519

M. Labussiere, A. Idbaih, and X. Wang, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2, Neurology, vol.74, issue.23, pp.1886-1890, 2010.
DOI : 10.1212/WNL.0b013e3181e1cf3a

F. Ducray, E. Criniere, and A. Idbaih, ??-Internexin expression identifies 1p19q codeleted gliomas, Neurology, vol.72, issue.2, pp.156-161, 2009.
DOI : 10.1212/01.wnl.0000339055.64476.cb

C. Goze, V. Rigau, L. Gibert, T. Maudelonde, and H. Duffau, Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis?, Journal of Neuro-Oncology, vol.58, issue.3, pp.1-5, 2009.
DOI : 10.1016/S0002-9440(10)64183-1

C. Houillier, K. Mokhtari, and C. Carpentier, Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas, Neuro-Oncology, vol.88, issue.3, pp.2-6, 2010.
DOI : 10.1007/s11060-008-9563-z

C. Hartmann, B. Hentschel, and M. Tatagiba, Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? Clin Cancer Res, pp.4588-4599, 2011.

T. Watanabe, Y. Katayama, and C. Komine, O6-methylguanine-DNA methyltransferase methylation andTP53 mutation in malignant astrocytomas and their relationships with clinical course, International Journal of Cancer, vol.52, issue.4, pp.581-587, 2005.
DOI : 10.1016/S0027-5107(00)00022-1

C. Hartmann, J. Meyer, and J. Balss, Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas, Acta Neuropathologica, vol.324, issue.2, pp.469-474, 2009.
DOI : 10.1007/BF00284430

H. Yan, D. Parsons, and G. Jin, Mutations in Gliomas, New England Journal of Medicine, vol.360, issue.8, pp.765-773, 2009.
DOI : 10.1056/NEJMoa0808710

M. Sanson, Y. Marie, and S. Paris, Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas, Journal of Clinical Oncology, vol.27, issue.25, pp.4150-4154, 2009.
DOI : 10.1200/JCO.2009.21.9832

T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki, IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas, The American Journal of Pathology, vol.174, issue.4, pp.1149-1153, 2009.
DOI : 10.2353/ajpath.2009.080958

S. Everhard, G. Kaloshi, and E. Criniere, MGMT methylation: A marker of response to temozolomide in low-grade gliomas, Annals of Neurology, vol.97, issue.6, pp.740-743, 2006.
DOI : 10.1093/jnen/60.8.808

R. Stupp, M. Hegi, and W. Mason, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-466, 2009.
DOI : 10.1016/S1470-2045(09)70025-7

M. Mollemann, M. Wolter, J. Felsberg, V. Collins, and G. Reifenberger, gene in oligodendroglial tumors, International Journal of Cancer, vol.188, issue.3, pp.379-385, 2005.
DOI : 10.1016/S0304-3835(02)00198-2

N. Levin, I. Lavon, and B. Zelikovitsh, Progressive low-grade oligodendrogliomas, Cancer, vol.68, issue.8, pp.1759-1765, 2006.
DOI : 10.1093/jnen/63.4.314

L. Huang, T. Jiang, and F. Yuan, -methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study, Neuropathology and Applied Neurobiology, vol.31, issue.4, pp.367-379, 2009.
DOI : 10.1212/01.WNL.0000148642.26985.68

I. Lavon, D. Zrihan, and B. Zelikovitch, Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas, Clinical Cancer Research, vol.13, issue.5, pp.1429-1437, 2007.
DOI : 10.1158/1078-0432.CCR-06-2050

C. Houillier, X. Wang, and G. Kaloshi, IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas, Neurology, vol.75, issue.17, pp.1560-1566, 2011.
DOI : 10.1212/WNL.0b013e3181f96282

S. Kesari, D. Schiff, and J. Drappatz, Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults, Clinical Cancer Research, vol.15, issue.1, pp.330-337, 2009.
DOI : 10.1158/1078-0432.CCR-08-0888

C. Komine, T. Watanabe, and Y. Katayama, Promoter Hypermethylation of the DNA Repair Gene O6-Methylguanine-DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low-grade Diffuse Astrocytomas, Brain Pathology, vol.16, issue.2, pp.176-184, 2003.
DOI : 10.1093/jnen/60.12.1181

Y. Fu, R. Huang, and J. Du, Glioma-derived mutations in IDH: From mechanism to potential therapy, Biochemical and Biophysical Research Communications, vol.397, issue.2, pp.127-130, 2010.
DOI : 10.1016/j.bbrc.2010.05.115

D. Parsons, S. Jones, and X. Zhang, An Integrated Genomic Analysis of Human Glioblastoma Multiforme, Science, vol.25, issue.13, pp.1807-1812, 2008.
DOI : 10.1002/jcc.20084

D. Capper, H. Zentgraf, J. Balss, C. Hartmann, and A. Von-deimling, Monoclonal antibody specific for IDH1 R132H mutation, Acta Neuropathologica, vol.324, issue.5, pp.599-601, 2009.
DOI : 10.1007/s00401-009-0595-z

D. Capper, D. Reuss, and J. Schittenhelm, Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology, Acta Neuropathologica, vol.360, issue.2, pp.241-252, 2011.
DOI : 10.1056/NEJMoa0808710

M. Berger, A. Deliganis, J. Dobbins, and G. Keles, The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas, Cancer, vol.35, issue.6, pp.1784-1791, 1994.
DOI : 10.1016/0360-3016(77)90045-1

N. Sanai and M. Berger, GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME, Neurosurgery, vol.78, issue.4, pp.753-764, 2008.
DOI : 10.1259/bjr/28534346

N. Sanai and M. Berger, Operative techniques for gliomas and the value of extent of resection, Neurotherapeutics, vol.62, issue.3, pp.478-486, 2009.
DOI : 10.1227/01.neu.0000317304.31579.17

R. Ahmadi, C. Dictus, and C. Hartmann, Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients, Acta Neurochirurgica, vol.151, issue.11, pp.1359-1365, 2009.
DOI : 10.1007/s00701-009-0473-4

E. Shaw, B. Berkey, and S. Coons, Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial, Journal of Neurosurgery, vol.16, issue.98, pp.835-841, 2008.
DOI : 10.1016/S0140-6736(05)67070-5

E. Mandonnet, S. Jbabdi, and L. Taillandier, Preoperative estimation of residual volume for WHO grade II glioma resected with intraoperative functional mapping, Neuro-Oncology, vol.9, issue.1, pp.63-69, 2007.
DOI : 10.1259/bjr/28534346

URL : https://hal.archives-ouvertes.fr/inserm-00164361

N. Sanai and M. Berger, Intraoperative stimulation techniques for functional pathway preservation and glioma resection, Neurosurgical Focus, vol.69, issue.2, p.1, 2010.
DOI : 10.1259/bjr/28534346

H. Duffau, Awake Surgery for Nonlanguage Mapping, Neurosurgery, vol.7, issue.6, pp.523-528, 2010.
DOI : 10.1212/WNL.57.5.871

H. Duffau, P. Gatignol, S. Mandonnet, E. Capelle, L. Taillandier et al., Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere, Journal of Neurosurgery, vol.51, issue.1, pp.461-471, 2008.
DOI : 10.1016/j.ejrad.2005.04.010

H. Duffau, L. Capelle, and D. Denvil, Usefulness of intraoperative electrical subcortical mapping during surgery for low-grade gliomas located within eloquent brain regions: functional results in a consecutive series of 103 patients, Journal of Neurosurgery, vol.195, issue.4, pp.764-778, 2003.
DOI : 10.3171/jns.1996.85.4.0542

H. Duffau, M. Lopes, and F. Arthuis, Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution, Journal of Neurology, Neurosurgery & Psychiatry, vol.76, issue.6, pp.845-851, 2005.
DOI : 10.1136/jnnp.2004.048520

R. Soffietti, B. Baumert, and L. Bello, Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force, European Journal of Neurology, vol.27, issue.9, pp.1124-1133, 2010.
DOI : 10.1200/JCO.2008.20.5765

E. Chang, A. Clark, and J. Smith, Functional mapping???guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival, Journal of Neurosurgery, vol.42, issue.3, pp.566-573, 2011.
DOI : 10.1016/S0140-6736(05)67070-5

J. Martino, L. Taillandier, S. Moritz-gasser, P. Gatignol, and H. Duffau, Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas, Acta Neurochirurgica, vol.78, issue.5, pp.427-436, 2009.
DOI : 10.1093/jnen/61.3.215

F. Vergani, M. Sanson, and H. Duffau, Combined multiple surgical intervention and chemotherapy for multicentric WHO grade II glioma, Acta Neurochirurgica, vol.68, issue.12, pp.1699-1704, 2009.
DOI : 10.1016/S0035-3787(06)75088-3

Y. Yordanova, S. Moritz-gasser, and H. Duffau, Awake surgery for WHO Grade II gliomas within ???noneloquent??? areas in the left dominant hemisphere: toward a ???supratotal??? resection, Journal of Neurosurgery, vol.56, issue.2, 2011.
DOI : 10.1016/j.neuroimage.2005.11.002

M. Benzagmout, P. Gatignol, and H. Duffau, Resection of World Health Organization Grade Ii Gliomas Involving Broca's Area: Methodological and Functional Considerations, Neurosurgery, vol.78, issue.4, pp.741-752, 2007.
DOI : 10.1259/bjr/28534346

H. Duffau, A personal consecutive series of surgically treated 51 cases of insular WHO Grade II glioma: advances and limitations, Journal of Neurosurgery, vol.4, issue.4, pp.696-708, 2009.
DOI : 10.3171/jns.1996.85.2.0263

K. Gehring, M. Sitskoorn, and C. Gundy, Cognitive Rehabilitation in Patients With Gliomas: A Randomized, Controlled Trial, Journal of Clinical Oncology, vol.27, issue.22, pp.3712-3722, 2009.
DOI : 10.1200/JCO.2008.20.5765

A. Karim, B. Maat, and R. Hatlevoll, A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844, International Journal of Radiation Oncology*Biology*Physics, vol.36, issue.3, pp.549-556, 1996.
DOI : 10.1016/S0360-3016(96)00352-5

E. Shaw, R. Arusell, and B. Scheithauer, Prospective Randomized Trial of Low- Versus High-Dose Radiation Therapy in Adults With Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study, Journal of Clinical Oncology, vol.20, issue.9, pp.2267-2276, 2002.
DOI : 10.1200/JCO.2002.09.126

G. Kiebert, D. Curran, and N. Aaronson, Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised Phase III trial on dose response (EORTC trial 22844), European Journal of Cancer, vol.34, issue.12, pp.1902-1909, 1998.
DOI : 10.1016/S0959-8049(98)00268-8

M. Van-den-bent, D. Afra, and O. De-witte, Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial, The Lancet, vol.366, issue.9490, pp.985-990, 2005.
DOI : 10.1016/S0140-6736(05)67070-5

E. Shaw, M. Wang, and S. Coons, Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.2006

R. Kortmann, B. Jeremic, and M. Weller, Sofortige postoperative Strahlentherapie oder abwartende Haltung bei der Behandlung niedrigmaligner Gliome im Erwachsenenalter?, Strahlentherapie und Onkologie, vol.180, issue.7, pp.408-418, 2004.
DOI : 10.1007/s00066-004-1221-6

L. Douw, M. Klein, and S. Fagel, Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up, The Lancet Neurology, vol.8, issue.9, pp.810-818, 2009.
DOI : 10.1016/S1474-4422(09)70204-2

M. Swennen, J. Bromberg, and T. Witkamp, Delayed Radiation Toxicity after Focal or Whole Brain Radiotherapy for Low-Grade Glioma, Journal of Neuro-Oncology, vol.66, issue.3, pp.333-339, 2004.
DOI : 10.1023/B:NEON.0000014518.16481.7e

T. Postma, M. Klein, and C. Verstappen, Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma, Neurology, vol.59, issue.1, pp.121-123, 2002.
DOI : 10.1212/WNL.59.1.121

M. Klein, J. Heimans, and N. Aaronson, Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study, The Lancet, vol.360, issue.9343, pp.1361-1368, 2002.
DOI : 10.1016/S0140-6736(02)11398-5

M. Taphoorn, J. Heimans, E. Van-der-veen, and A. Karim, Endocrine functions in long-term survivors of low-grade supratentorial glioma treated with radiation therapy, Journal of Neuro-Oncology, vol.123, issue.2, pp.97-102, 1995.
DOI : 10.1111/j.1651-2227.1989.tb11249.x

H. Eyre, J. Crowley, and J. Townsend, A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study, Journal of Neurosurgery, vol.18, issue.6, pp.909-914, 1993.
DOI : 10.3171/jns.1989.71.4.0487

D. Macdonald, L. Gaspar, and J. Cairncross, Successful chemotherapy for newly diagnosed aggressive oligodendroglioma, Annals of Neurology, vol.59, issue.5, pp.573-574, 1990.
DOI : 10.1002/ana.410270519

W. Mason, G. Krol, and L. Deangelis, Low-grade oligodendroglioma responds to chemotherapy, Neurology, vol.46, issue.1, pp.203-207, 1996.
DOI : 10.1212/WNL.46.1.203

R. Soffietti, R. Rudà, G. Bradac, and D. Schiffer, PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas, Neurosurgery, vol.68, issue.5, pp.1066-1073, 1998.
DOI : 10.3171/jns.1988.68.5.0684

J. Buckner, D. Gesme, J. O-'fallon, and J. , Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities, Journal of Clinical Oncology, vol.21, issue.2, pp.251-255, 2003.
DOI : 10.1200/JCO.2003.06.023

E. Stege, J. Kros, and H. De-bruin, Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine, Cancer, vol.52, issue.4, pp.802-809, 2005.
DOI : 10.1016/S0167-8140(96)91782-X

C. Lebrun, D. Fontaine, and V. Bourg, Treatment of newly diagnosed symptomatic pure lowgrade oligodendrogliomas with PCV chemotherapy Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group, Eur J Neurol. Neurology, vol.1451, issue.127, pp.391-3981140, 1998.

T. Postma, C. Van-groeningen, and R. Witjes, Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma, Journal of Neuro-Oncology, vol.38, issue.1, pp.69-75, 1998.
DOI : 10.1023/A:1005909318270

J. Vesper, E. Graf, and C. Wille, Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors, BMC Neurology, vol.31, issue.1, p.33, 2009.
DOI : 10.1053/j.seminoncol.2004.07.006

M. Brada, L. Viviers, and C. Abson, Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas, Annals of Oncology, vol.14, issue.12, pp.1715-1721, 2003.
DOI : 10.1093/annonc/mdg371

J. Quinn, D. Reardon, and A. Friedman, Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma, Journal of Clinical Oncology, vol.21, issue.4, pp.646-651, 2003.
DOI : 10.1200/JCO.2003.01.009

A. Pace, A. Vidiri, and E. Galie, Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response, Annals of Oncology, vol.14, issue.12, pp.1722-1726, 2003.
DOI : 10.1093/annonc/mdg502

M. Van-den-bent, M. Taphoorn, and A. Brandes, Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971, Journal of Clinical Oncology, vol.21, issue.13, pp.2525-2528, 2003.
DOI : 10.1200/JCO.2003.12.015

G. Kaloshi, A. Benouaich-amiel, and F. Diakite, Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome, Neurology, vol.68, issue.21, pp.1831-1836, 2007.
DOI : 10.1212/01.wnl.0000262034.26310.a2

C. Brock, E. Newlands, and S. Wedge, Phase I trial of temozolomide using an extended continuous oral schedule, Cancer Res, vol.58, pp.4363-4367, 1998.

M. Wyss, S. Hofer, and M. Bruehlmeier, Early metabolic responses in temozolomide treated low-grade glioma patients, Journal of Neuro-Oncology, vol.67, issue.1, pp.87-93, 2009.
DOI : 10.1097/nen.0b013e31815f65fb

N. Pouratian, J. Gasco, J. Sherman, M. Shaffrey, and D. Schiff, Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas, Journal of Neuro-Oncology, vol.52, issue.3, pp.281-288, 2007.
DOI : 10.1179/joc.2005.17.6.674

A. Tosoni, E. Franceschi, and M. Ermani, Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas, Journal of Neuro-Oncology, vol.13, issue.2, pp.179-185, 2008.
DOI : 10.1111/j.1750-3639.2003.tb00017.x

M. Blonski, L. Taillandier, and G. Herbet, Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life, Journal of Neuro-Oncology, vol.6, issue.2, 2011.
DOI : 10.1037/h0054651

J. Olson, E. Riedel, and L. Deangelis, Long-term outcome of low-grade oligodendroglioma and mixed glioma, Neurology, vol.54, issue.7, pp.1442-1448, 2000.
DOI : 10.1212/WNL.54.7.1442

H. Duffau, Brain plasticity: From pathophysiological mechanisms to therapeutic applications, Journal of Clinical Neuroscience, vol.13, issue.9, pp.885-897, 2006.
DOI : 10.1016/j.jocn.2005.11.045

URL : https://hal.archives-ouvertes.fr/inserm-00163803

D. Vita, S. , D. Matteis, S. Laurenti, and L. , Secondary Ph+ acute lymphoblastic leukemia after temozolomide, Annals of Hematology, vol.33, issue.4, pp.760-762, 2005.
DOI : 10.1007/s00277-005-1093-6

E. Yaman, U. Coskun, and B. Ozturk, Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma, Journal of Clinical Neuroscience, vol.16, issue.4, pp.591-592, 2009.
DOI : 10.1016/j.jocn.2008.05.030

J. Villano, N. Letarte, J. Yu, S. Abdur, and L. Bressler, Hematologic adverse events associated with temozolomide, Cancer Chemotherapy and Pharmacology, vol.45, issue.1, 2011.
DOI : 10.1136/jmg.2007.053850

A. Shaikh and N. Masood, Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report, Journal of Medical Case Reports, vol.107, issue.1, p.274, 2010.
DOI : 10.1182/blood-2005-09-3649

R. Jalali, P. Singh, H. Menon, and S. Gujral, Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide, Journal of Neuro-Oncology, vol.91, issue.1, pp.105-107, 2007.
DOI : 10.1007/s11060-007-9398-z

V. Noronha, N. Berliner, and K. Ballen, Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1, Neuro-Oncology, vol.8, issue.3, pp.280-283, 2006.
DOI : 10.1007/s11060-004-2028-0

Y. Su, M. Chang, M. Chiang, and R. Hsieh, Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma, Journal of Neuro-Oncology, vol.43, issue.6, pp.315-318, 2005.
DOI : 10.1007/s11060-004-2028-0

E. Morris, K. Kasow, U. Reiss, D. Ellison, and A. Broniscer, Bone marrow transplantation for severe aplastic anemia secondary to temozolomide, Journal of Neuro-Oncology, vol.7, issue.5, pp.237-239, 2009.
DOI : 10.1007/s11060-008-9704-4

G. Comez, A. Sevinc, and O. Sever, An Unusual Case of Aplastic Anemia Caused by Temozolomide, Case Reports in Medicine, vol.23, issue.1546, p.975039, 2010.
DOI : 10.1016/S1470-2045(06)70696-9

A. Sharma, D. Gupta, and B. Mohanti, Non-Hodgkin lymphoma following temozolomide, Pediatric Blood & Cancer, vol.91, issue.4, pp.661-662, 2009.
DOI : 10.1002/pbc.22090

J. Villano, C. Collins, E. Manasanch, C. Ramaprasad, and K. Van-besien, Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide, The Lancet Oncology, vol.7, issue.5, pp.436-438, 2006.
DOI : 10.1016/S1470-2045(06)70696-9

. Duke, . University, . And, and P. Novartis, Phase II imatinib + hydroxyurea in treatment of patients with recurrent/progressive grade II low-grade glioma (LGG), 2009.

P. Brown, J. Buckner, O. Fallon, and J. , Effects of Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma Measured by the Folstein Mini-Mental State Examination, Journal of Clinical Oncology, vol.21, issue.13, pp.2519-2524, 2003.
DOI : 10.1200/JCO.2003.04.172

P. Brown, J. Buckner, O. Fallon, and J. , Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma, International Journal of Radiation Oncology*Biology*Physics, vol.59, issue.1, pp.117-125, 2004.
DOI : 10.1016/j.ijrobp.2003.10.040

M. Klein and J. Heimans, The Measurement of Cognitive Functioning in Low-Grade Glioma Patients After Radiotherapy, Journal of Clinical Oncology, vol.22, issue.5, pp.966-967, 2004.
DOI : 10.1200/JCO.2004.99.290

C. Meyers and K. Hess, Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progression, Neuro-Oncology, vol.5, issue.2, pp.89-95, 2003.
DOI : 10.1002/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-Q

P. Brown, J. Buckner, J. Uhm, and E. Shaw, The neurocognitive effects of radiation in adult low-grade glioma patients, Neuro-Oncology, vol.5, issue.3, pp.161-167, 2003.
DOI : 10.1007/BF01476278

C. Armstrong, J. Hunter, and G. Ledakis, Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings, Neurology, vol.59, issue.1, pp.40-48, 2002.
DOI : 10.1212/WNL.59.1.40

N. Laack, P. Brown, and R. Ivnik, Cognitive function after radiotherapy for supratentorial low-grade glioma: A North Central Cancer Treatment Group prospective study, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.4, pp.1175-1183, 2005.
DOI : 10.1016/j.ijrobp.2005.04.016

O. Tucha, C. Smely, M. Preier, and K. Lange, Cognitive Deficits before Treatment among Patients with Brain Tumors, Neurosurgery, vol.22, issue.2, pp.324-333, 2000.
DOI : 10.1227/00006123-198805000-00012

M. Taphoorn, Neurocognitive sequelae in the treatment of low-grade gliomas, Seminars in Oncology, vol.30, pp.45-48, 2003.
DOI : 10.1053/j.seminoncol.2003.11.023

M. Klein, J. Heimans, and N. Aaronson, Impaired cognitive functioning in low-grade glioma patients: relationship to tumor localisation, radiotherapy and the use of anticonvulsants], Ned Tijdschr Geneeskd, vol.148, pp.2175-2180, 2004.

P. Teixidor, P. Gatignol, and M. Leroy, Assessment of verbal working memory before and after surgery for low-grade glioma, Journal of Neuro-Oncology, vol.97, issue.3, pp.305-313, 2007.
DOI : 10.1007/s11060-006-9233-y

URL : https://hal.archives-ouvertes.fr/inserm-00164424

B. Goldstein, J. Obrzut, C. John, J. Hunter, and C. Armstrong, The Impact of Low-Grade Brain Tumors on Verbal Fluency Performance Bram Goldstein, Journal of Clinical and Experimental Neuropsychology, vol.26, issue.6, pp.750-758, 2004.
DOI : 10.1080/13803390490509376

M. Taphoorn, J. Heimans, F. Snoek, J. Lindeboom, and A. Karim, Quality of life and neuropsychological functions in long-term low-grade glioma survivors, International Journal of Radiation Oncology*Biology*Physics, vol.29, issue.5, pp.1201-1202, 1994.
DOI : 10.1016/0360-3016(94)90423-5

J. Reijneveld, M. Sitskoorn, M. Klein, J. Nuyen, and M. Taphoorn, Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas, Neurology, vol.56, issue.5, pp.618-623, 2001.
DOI : 10.1212/WNL.56.5.618

L. Ek, O. Almkvist, M. Wiberg, G. Stragliotto, and A. Smits, Early cognitive impairment in a subset of patients with presumed low-grade glioma, Neurocase, vol.15, issue.6, pp.503-511, 2010.
DOI : 10.1111/j.1600-0447.1983.tb09716.x

M. Ruge, J. Ilmberger, J. Tonn, and F. Kreth, Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade??II glioma: status prior to therapy, Journal of Neuro-Oncology, vol.27, issue.9, pp.129-136, 2011.
DOI : 10.1200/JCO.2008.20.5765

G. Sheline, W. Wara, and V. Smith, Therapeutic irradiation and brain injury, International Journal of Radiation Oncology*Biology*Physics, vol.6, issue.9, pp.1215-1228, 1980.
DOI : 10.1016/0360-3016(80)90175-3

T. Byrne, Cognitive sequelae of brain tumor treatment, Current Opinion in Neurology, vol.18, issue.6, pp.662-666, 2005.
DOI : 10.1097/01.wco.0000191511.52745.99

G. Welzel, S. Steinvorth, and F. Wenz, Kognitive Leistungsf??higkeit von Erwachsenen nach Chemo- und/oder kranieller Strahlentherapie, Strahlentherapie und Onkologie, vol.181, issue.3, pp.141-156, 2005.
DOI : 10.1007/s00066-005-1351-5

J. Vardy and I. Tannock, Cognitive function after chemotherapy in adults with solid tumours, Critical Reviews in Oncology/Hematology, vol.63, issue.3, pp.183-202, 2007.
DOI : 10.1016/j.critrevonc.2007.06.001

E. Davies, S. Hall, and C. Clarke, Two year survival after malignant cerebral glioma: patient and relative reports of handicap, psychiatric symptoms and rehabilitation, Disability and Rehabilitation, vol.25, issue.6, pp.259-266, 2003.
DOI : 10.1080/0963828021000024915

K. Gehring, N. Aaronson, M. Taphoorn, and M. Sitskoorn, A description of a cognitive rehabilitation programme evaluated in brain tumour patients with mild to moderate cognitive deficits, Clinical Rehabilitation, vol.10, issue.5, 2011.
DOI : 10.1016/j.brat.2009.01.010

E. Shaw, R. Rosdhal, D. Agostino, and R. Jr, Phase II Study of Donepezil in Irradiated Brain Tumor Patients: Effect on Cognitive Function, Mood, and Quality of Life, Journal of Clinical Oncology, vol.24, issue.9, pp.1415-1420, 2006.
DOI : 10.1200/JCO.2005.03.3001

J. Wefel, Effects of methylphenidate versus sustained release methylphenidate on cognitive functioning, 418691.

S. Rapp, Donepezil in treating patients who have undergone radiation therapy for brain tumors, p.369785

E. Shaw, Armodafinil in treating fatigue caused by radiation therapy in patients with primary brain tumors, 1032200.

M. Scerrati, P. Montemaggi, M. Iacoangeli, R. Roselli, and G. Rossi, Interstitial brachytherapy for low-grade cerebral gliomas: Analysis of results in a series of 36 cases, Acta Neurochirurgica, vol.99, issue.Suppl, pp.97-105, 1994.
DOI : 10.1007/978-3-642-68178-3_1

L. Lunsford, S. Somaza, D. Kondziolka, and J. Flickinger, Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma, Journal of Neurosurgery, vol.3, issue.4, pp.523-529, 1995.
DOI : 10.1016/0360-3016(90)90397-3

M. Van-kampen, R. Engenhart-cabillic, and J. Debus, Low-grade astrocytoma: treatment with conventionally fractionated stereotactic radiation therapy., Radiology, vol.201, issue.1, pp.275-278, 1996.
DOI : 10.1148/radiology.201.1.8816559

N. Mackworth, P. Fobair, and M. Prados, Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores, Journal of Neuro-Oncology, vol.14, issue.3, pp.243-253, 1992.
DOI : 10.1007/BF00172600

M. Taphoorn, J. Heimans, and F. Snoek, Assessment of quality of life in patients treated for low-grade glioma: a preliminary report., Journal of Neurology, Neurosurgery & Psychiatry, vol.55, issue.5, pp.372-376, 1992.
DOI : 10.1136/jnnp.55.5.372

M. Taphoorn, A. Schiphorst, and F. Snoek, Cognitive functions and quality of life in patients with low-grade gliomas: The impact of radiotherapy, Annals of Neurology, vol.47, issue.1, pp.48-54, 1994.
DOI : 10.1001/archneur.1990.00530040039017

J. Bampoe, N. Laperriere, and M. Pintilie, Quality of life in patients with glioblastoma participating in a randomized study of boost brachytherapy, Journal of Neurosurgery, vol.45, issue.6, pp.917-926, 2000.
DOI : 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q

P. Brown, K. Ballman, and T. Rummans, Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas, Journal of Neuro-Oncology, vol.2, issue.Suppl 1, pp.283-291, 2006.
DOI : 10.4088/JCP.v61n0608

A. Budrukkar, R. Jalali, and D. Dutta, Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice, Journal of Neuro-Oncology, vol.90, issue.3, pp.413-419, 2009.
DOI : 10.1007/s11060-009-9810-y

C. Hahn, R. Dunn, and P. Logue, Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors, International Journal of Radiation Oncology*Biology*Physics, vol.55, issue.4, pp.992-999, 2003.
DOI : 10.1016/S0360-3016(02)04205-0

R. Liu, K. Solheim, and M. Polley, Quality of life in low-grade glioma patients receiving temozolomide, Neuro-Oncology, vol.11, issue.1, pp.59-68, 2009.
DOI : 10.1023/A:1023900802254

D. Osoba, M. Brada, W. Yung, and M. Prados, Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.18, issue.7, pp.1481-1491, 2000.
DOI : 10.1200/JCO.2000.18.7.1481

M. Janda, S. Steginga, and D. Langbecker, Quality of life among patients with a brain tumor and their carers, Journal of Psychosomatic Research, vol.63, issue.6, pp.617-623, 2007.
DOI : 10.1016/j.jpsychores.2007.06.018

N. Aaronson, S. Ahmedzai, and B. Bergman, The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, JNCI Journal of the National Cancer Institute, vol.85, issue.5, pp.365-376, 1993.
DOI : 10.1093/jnci/85.5.365

M. Gustafsson, T. Edvardsson, and G. Ahlstrom, The relationship between function, quality of life and coping in patients with low-grade gliomas, Supportive Care in Cancer, vol.111, issue.6, pp.1205-1212, 2006.
DOI : 10.7326/0003-4819-111-6-517

L. Dinapoli, M. Maschio, and B. Jandolo, Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study, Neurological Sciences, vol.5, issue.4, 2009.
DOI : 10.1001/archinte.1951.03810040002001

A. Mainio, S. Tuunanen, and H. Hakko, Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003, European Archives of Psychiatry and Clinical Neuroscience, vol.76, issue.5, pp.516-521, 1990.
DOI : 10.1111/j.1532-5415.2000.tb03886.x

G. Pelletier, M. Verhoef, N. Khatri, and N. Hagen, Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues, Journal of Neuro-Oncology, vol.57, issue.1, pp.41-49, 2002.
DOI : 10.1023/A:1015728825642

K. Struik, M. Klein, and J. Heimans, Fatigue in low-grade glioma, Journal of Neuro-Oncology, vol.256, issue.1, pp.73-78, 2009.
DOI : 10.1038/bjc.1998.600

E. Mandonnet, H. Duffau, and L. Bauchet, A new tool for grade??II glioma studies: plotting cumulative time with quality of life versus time to malignant transformation, Journal of Neuro-Oncology, vol.4, issue.1, 2011.
DOI : 10.1007/BF00172600

A. Pahlson, L. Ek, G. Ahlstrom, and A. Smits, Pitfalls in the Assessment of Disability in Individuals with Low-Grade Gliomas, Journal of Neuro-Oncology, vol.65, issue.2, pp.149-158, 2003.
DOI : 10.1023/B:NEON.0000003727.09448.dd

I. Lefkowitz, R. Packer, and S. Ryan, Late recurrence of primitive neuroectodermal Tumor/Medulloblastoma, Cancer, vol.60, issue.4, pp.826-830, 1988.
DOI : 10.1001/archneur.1975.00490530053004

A. Hu, Z. Xu, and R. Kim, Seizure control: A secondary benefit of chemotherapeutic temozolomide in brain cancer patients, Epilepsy Research, vol.95, issue.3, 2011.
DOI : 10.1016/j.eplepsyres.2011.03.018

H. Duffau, L. Capelle, and M. Lopes, Medically Intractable Epilepsy from Insular Low-Grade Gliomas: Improvement after an Extended Lesionectomy, Acta Neurochirurgica, vol.144, issue.6, pp.563-572, 2002.
DOI : 10.1007/s00701-002-0941-6

D. Englot, M. Berger, N. Barbaro, and E. Chang, Predictors of seizure freedom after resection of supratentorial low-grade gliomas, Journal of Neurosurgery, vol.18, issue.2, 2011.
DOI : 10.1097/00006123-199708000-00008

T. Danfors, D. Ribom, S. Berntsson, and A. Smits, Epileptic seizures and survival in early disease of grade 2 gliomas, European Journal of Neurology, vol.39, issue.7, pp.823-831, 2009.
DOI : 10.1016/S1052-5149(03)00090-X

M. Glantz, B. Cole, and P. Forsyth, Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors, Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, vol.54, pp.1886-1893, 2000.

M. Klein, N. Engelberts, and H. Van-der-ploeg, Epilepsy in low-grade gliomas: The impact on cognitive function and quality of life, Annals of Neurology, vol.342, issue.4, pp.514-520, 2003.
DOI : 10.1056/NEJM200002033420503

N. Engelberts, M. Klein, and H. Van-der-ploeg, Cognition and health-related quality of life in a well-defined subgroup of patients with partial epilepsy, Journal of Neurology, vol.249, issue.3, pp.294-299, 2002.
DOI : 10.1007/s004150200008

C. Brogna, G. Robles, S. Duffau, and H. , Brain tumors and epilepsy, Expert Review of Neurotherapeutics, vol.14, issue.6, pp.941-955, 2008.
DOI : 10.1093/annonc/mdg502

C. Vecht and E. Wilms, Seizures in low- and high-grade gliomas: current management and future outlook, Expert Review of Anticancer Therapy, vol.14, issue.5, pp.663-669, 2010.
DOI : 10.1093/annonc/mdg502

G. Bobustuc, C. Baker, and A. Limaye, Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide, Neuro-Oncology, vol.7, issue.5, pp.917-927, 2010.
DOI : 10.1093/carcin/20.12.2361

URL : https://academic.oup.com/neuro-oncology/article-pdf/12/9/917/16662992/noq044.pdf

M. Desmurget, F. Bonnetblanc, and H. Duffau, Contrasting acute and slow-growing lesions: a new door to brain plasticity, Brain, vol.130, issue.4, pp.898-914, 2007.
DOI : 10.1093/brain/awl300

URL : https://hal.archives-ouvertes.fr/inserm-00164411

F. Bonnetblanc, M. Desmurget, and H. Duffau, Gliomes de bas grade et plasticit?? c??r??brale, m??decine/sciences, vol.22, issue.4, pp.389-394, 2006.
DOI : 10.1051/medsci/2006224389

URL : http://www.medecinesciences.org/articles/medsci/pdf/2006/05/medsci2006224p389.pdf

H. Duffau and L. Capelle, Functional recuperation after resection of gliomas infiltrating primary somatosensory fields. Study of perioperative electric stimulation], Neurochirurgie, vol.47, pp.534-541, 2001.

D. Fontaine, L. Capelle, and H. Duffau, Somatotopy of the supplementary motor area: evidence from correlation of the extent of surgical resection with the clinical patterns of deficit, Neurosurgery, vol.50, pp.297-303, 2002.

H. Duffau, L. Taillandier, P. Gatignol, and L. Capelle, The insular lobe and brain plasticity: Lessons from tumor surgery, Clinical Neurology and Neurosurgery, vol.108, issue.6, pp.543-548, 2006.
DOI : 10.1016/j.clineuro.2005.09.004

URL : https://hal.archives-ouvertes.fr/inserm-00163816

H. Duffau, L. Capelle, and D. Denvil, Functional recovery after surgical resection of low grade gliomas in eloquent brain: hypothesis of brain compensation, Journal of Neurology, Neurosurgery & Psychiatry, vol.74, issue.7, pp.901-907, 2003.
DOI : 10.1136/jnnp.74.7.901

H. Duffau, D. Denvil, and L. Capelle, Absence of movement disorders after resection of glioma invading the right striatum, Journal of Neurosurgery, vol.152, issue.2, pp.363-369, 2002.
DOI : 10.1097/00006123-199801000-00005

H. Duffau, D. Denvil, and L. Capelle, Long term reshaping of language, sensory, and motor maps after glioma resection: a new parameter to integrate in the surgical strategy, J Neurol Neurosurg Psychiatry, vol.72, pp.511-516, 2002.

S. Robles, P. Gatignol, S. Lehericy, and H. Duffau, Long-term brain plasticity allowing a multistage surgical approach to World Health Organization Grade II gliomas in eloquent areas, Journal of Neurosurgery, vol.79, issue.4, pp.615-624, 2008.
DOI : 10.1161/01.STR.0000174487.81126.ef

H. Duffau, Does post-lesional subcortical plasticity exist in the human brain?, Neuroscience Research, vol.65, issue.2, pp.131-135, 2009.
DOI : 10.1016/j.neures.2009.07.002

T. Ius, E. Angelini, M. De-schotten, E. Mandonnet, and H. Duffau, Evidence for potentials and limitations of brain plasticity using an atlas of functional resectability of WHO grade II gliomas: Towards a ???minimal common brain???, NeuroImage, vol.56, issue.3, pp.992-1000, 2011.
DOI : 10.1016/j.neuroimage.2011.03.022

M. Catani, From hodology to function, Brain, vol.54, issue.6, pp.602-605, 2007.
DOI : 10.1002/mrm.20642

E. Mandonnet, J. Pallud, and O. Clatz, Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm, Neurosurgical Review, vol.20, issue.6, pp.263-269, 2008.
DOI : 10.1016/S0028-3770(05)83486-1

M. Berger, Functional mapping-guided resection of low-grade gliomas, Clin Neurosurg, vol.42, pp.437-452, 1995.

H. Duffau, Intraoperative cortico???subcortical stimulations in surgery of low-grade gliomas, Expert Review of Neurotherapeutics, vol.12, issue.4, pp.473-485, 2005.
DOI : 10.1097/00001756-200107200-00023

H. Duffau, Contribution of cortical and subcortical electrostimulation in brain glioma surgery: Methodological and functional considerations, Neurophysiologie Clinique/Clinical Neurophysiology, vol.37, issue.6, pp.373-382, 2007.
DOI : 10.1016/j.neucli.2007.09.003

W. Palmisano, K. Divine, and G. Saccomanno, Predicting lung cancer by detecting aberrant promoter methylation in sputum, Cancer Res, vol.60, pp.5954-5958, 2000.

J. Balss, J. Meyer, and W. Mueller, Analysis of the IDH1 codon 132 mutation in brain tumors, Acta Neuropathologica, vol.6, issue.6, pp.597-602, 2008.
DOI : 10.1093/jnen/59.6.544

Y. Sonoda, T. Kumabe, and T. Nakamura, mutations in Japanese glioma patients, Cancer Science, vol.324, issue.10, pp.1996-1998, 2009.
DOI : 10.1016/B978-0-12-152827-0.50009-8